SNB-101

SNB-101 is a novel nanoparticle anticancer drug that represents a significant advancement in cancer treatment technology. It is the first nanoparticle formulation of SN-38, which is the active metabolite of irinotecan. It was developed by SN Bioscience using their proprietary dual nano-micelle delivery system (DUCS) technology[1][3]. This innovative approach addresses the challenge of delivering the extremely insoluble SN-38 by incorporating it into polymer nanoparticles[8]. The drug has shown particular promise in treating small cell lung cancer (SCLC), an aggressive form of lung cancer with poor prognosis. SCLC represents 12-15% of all lung cancer cases, with approximately 70% of patients diagnosed at an extensive stage where the cancer has already spread, resulting in a five-year survival rate of less than 7%[5]. ## Development Status SNB-101 has received several important designations from the FDA: - Orphan Drug Designation for SCLC in July 2023[9] - Orphan Drug Designation for pancreatic cancer in February 2024[9] - Fast Track Designation for SCLC in May 2024[1][3][6] The drug has successfully completed a Phase 1 trial (NCT04640480) in patients with various advanced solid tumors[3]. In January 2025, the FDA cleared an Investigational New Drug (IND) application for a Phase 1b/2 clinical trial of SNB-101[5][6]. ## Clinical Trial Results The Phase 1 trial evaluated SNB-101 in 21 patients with solid tumors at doses ranging from 5 mg/m² to 50 mg/m² administered intravenously every two weeks[3]. Results presented at the 2023 European Society for Medical Oncology (ESMO) Congress showed: - Objective response rate (ORR): 14.3% - Disease control rate (DCR): 42.9% - Partial responses in 3 patients with SCLC, non-small cell lung cancer (NSCLC), and rectal cancer - Median progression-free survival: 1.9 months - Median overall survival: 6.1 months Common treatment-related adverse effects included neutropenia (61.9%), white blood cell count decreases (28.6%), nausea (23.8%), anemia (19.0%), and platelet count decreases (19.0%)[3]. Despite relatively high rates of hematological adverse events, neutropenia was manageable, and the maximum tolerated dose was not reached during dose escalation[3]. ## Future Development SN Bioscience plans to initiate Phase 1b/2 clinical trials in Q2 2025[5]. The upcoming trial will: - Target patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) - Focus on dose escalation and optimization - Enroll approximately 55 patients - Be conducted across South Korea, the U.S., and Europe - Measure efficacy, safety, and pharmacokinetics as primary endpoints Following the dose optimization phase, the company plans to assess SNB-101's efficacy and safety in approximately 100 patients through a single-arm, single-dose, open-label monotherapy study[5][6]. If results are positive, SN Bioscience aims for early U.S. commercialization, with market entry expected as early as 2028[5]. The company initially aims to position SNB-101 as a second- or third-line treatment option for patients resistant to existing therapies, with the ultimate goal of establishing it as a first- or second-line standard treatment, potentially in combination with immuno-oncology agents[5][9].

Other names

SN-38 nanoparticleSN38 nanoparticleSN 38 nanoparticleSN-38 nano-micelleSN38 nano-micelleSN 38 nano-micelle